scholarly journals Cytotoxic and pro-apoptotic Effects of Spirulina Platensis Extract on PC-3 Prostate Adenocarcinoma Cell Line

2022 ◽  
Author(s):  
Mohammad Reisi ◽  
Leila Rouhi ◽  
Khalil Khashei Varnamkhasti
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Incubation Time ◽  
Spirulina Platensis ◽  
Prostatic Cancer ◽  
Prostate Adenocarcinoma ◽  
Control Group ◽  
Adenocarcinoma Cell Line ◽  
Adenocarcinoma Cell ◽  
Apoptotic Effects

Introduction: Prostate cancer is one of the most common cancers among men, with an increasing incidence and mortality rate. In the present study, cytotoxic and pro-apoptotic effects of spirulina platensis extract on PC-3 prostate adenocarcinoma cell line were investigated. Methods: In the present experimental study, the PC-3 prostatic cancer cells were treated in four experimental with 400, 200, 100 and 50 μg / ml extract of spirulina and incubated at 24 and 48 hours. Cytotoxicity was analyzed by MTS kit (3-(4, 5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium, Inner Salt) and apoptosis was analyzed by flow- cytometry using an Annexin V-FITC/PI kit according to the manufacturer protocol in both times. Statistical analysis was accomplished by ANOVA and Duncan tests using FlowJo and SPSS 16 software. Results: In the experimental groups treated with extract of spirulina, the viability of the cells showed a decrease compared to control group, while this decrease was more noticeable in the experimental group of 100 μg / ml at both incubation times (<0.0071).Increased incidence of apoptosis was significantly higher in the experimental groups than the control group. However, this increase was significantly higher than the control group at concentrations of 200 μg / ml in 24h incubation time (Ƥ < 0.0331) and 100 μg / ml of 48h incubation time (Ƥ < 0.0502). Conclusion: Extract of Spirulina at specific concentrations reduced cell growth and induced apoptosis in PC-3 prostatic cancer cells. Evidence suggests that spirulina can be used as an anticancer drug for the treatment of prostate cancer.

scholarly journals Antiproliferative and apoptotic effects of pinocembrin in human prostate cancer cells

2013 ◽  
Vol 8 (3) ◽  
Author(s):  
Zhenyu Chen ◽  
Azhar Rasul ◽  
Chaoyue Zhao ◽  
Faya Martin Millimouno ◽  
Ichiro Tsuji ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Apoptotic Effects

scholarly journals ESTAT3 Inhibitor AG-490 Inhibits the Growth of Prostate Cancer by miR-503-5p Both In Vivo and In Vitro

2020 ◽  
Vol 19 ◽  
pp. 153303382094806
Author(s):  
Guangxing Tan ◽  
Lin Jiang ◽  
Gangqin Li ◽  
Kuan Bai
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Nude Mouse ◽  
Luciferase Reporter ◽  
Control Group ◽  
Dependent Manner ◽  
Prostate Cancer Cells ◽  
Mouse Xenograft Model ◽  
Pc3 Cells ◽  
Du145 Cells

Objective: To explore the effect and the related mechanism of STAT3 inhibitor AG-490 on inhibiting the proliferation of prostate cancer cells. Methods: PC3 cells and DU145 cells were cultured stably and treated with AG-490 to detect the changes in the activity of PC3 cells and DU145 cells. Thirty 6-8 weeks male BALB/c nude mouse were randomly divided into a control group, a DMSO group, and an AG-490 group to detect differences in various indexes . Results: The overexpression of miR-503-5p depends on the activation of STAT3. After treatment with AG-490, The proliferation and invasion of PC3 cells and DU145 cells and the expression of miR-503-5p were all reduced. Luciferase reporter assay demonstrated that the target proteins of miR-503-5p include PDCD4, TIMP-3, and PTEN. After treatment with AG-490, the expression of PDCD4, TIMP-3, and PTEN in cells was significantly up-regulated. IL-6-induced overexpression of miR-503-5p and restored the expression of STAT3, demonstrating the correlation between STAT3 and miR-503-5p. AG-490 can inhibit tumor growth and induce tumor cell apoptosis in the PC3 BALB/c nude mouse xenograft model. Western blotting and immunohistochemical staining showed that the expression levels of STAT3, Ki67, Bcl-2 and MMP-2 in the AG-490 group were significantly reduced, and the expression of PDCD4, TIMP-3 and PTEN increased. Conclusion: AG-490 can inhibit the growth of prostate cancer cells in a miR-503-5p-dependent manner by targeting STAT3. AG-490 is expected to become a new candidate drug for the treatment of prostate cancer.

Abstract 3507: Rhamnetin enhances anti-proliferative and apoptotic effects on prostate cancer cells

2016 ◽  
Author(s):  
Riddhi Patel ◽  
Rebecca Pakradooni ◽  
Christine Oak ◽  
Natarajan Bhaskaran ◽  
Sanjeev Shukla
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Apoptotic Effects

Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate

2008 ◽  
Vol 270 (2) ◽  
pp. 277-285 ◽  
Author(s):  
Daniel Ezekwudo ◽  
Rangaiah Shashidharamurthy ◽  
Dilip Devineni ◽  
Erica Bozeman ◽  
Ravi Palaniappan ◽  
...  
Keyword(s):  
Cell Death ◽  
Methyl Jasmonate ◽  
Cell Line ◽  
Prostate Adenocarcinoma ◽  
Human Prostate ◽  
Adenocarcinoma Cell Line ◽  
Adenocarcinoma Cell ◽  
Apoptotic Protein

scholarly journals Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic Cancer

2019 ◽  
Vol 35 (5) ◽  
Author(s):  
Sumei Zhang ◽  
Shufen Zhao ◽  
Xinzhen Fu
Keyword(s):  
Prostate Cancer ◽  
Prostatic Cancer ◽  
Advanced Prostate Cancer ◽  
Intensity Modulated Radiotherapy ◽  
Control Group ◽  
Observation Group ◽  
Short Term ◽  
Advanced Prostatic Cancer ◽  
Intensity Modulated ◽  
Significant Difference

Objective: To evaluate the clinical efficacy of intensity modulated radiation therapy and endocrinotherapy for middle and advanced prostate cancer. Methods: Total 104 elderly patients with middle and advanced prostate cancer who were admitted to our hospital from November 2014 to August 2015 were selected using random number table method. They were divided into intensity-modulated radiotherapy combined with endocrinotherapy group (observation group) and conventional radiotherapy combined with endocrinotherapy group (control group), 52 each. The serum levels of prostate specific antigen (PSA) and free prostate antigen (f PSA) were measured three months after treatment. The short-term efficacy and toxic and side effects of the patients were observed, and the survival rate was recorded through three-year follow up. Results: The clinical effective rate of the observation group was 92.68%, and that of the control group was 70.73%; there was a significant difference between the two groups (P<0.05). The serum PSA and f PSA levels of the two groups were similar before treatment, but there was no significant difference (P>0.05). The serum PSA and f PSA levels after treatment were significantly lower than before treatment. The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). The one-year and three-year survival rates of the two groups were significantly different (90.0 vs. 80.0%, 60.0 vs. 43.3%, P>0.05). Conclusion: Intensity modulated radiotherapy combined with endocrinotherapy was safe and well tolerated in the treatment of middle and advanced prostate cancer. It can improve the short-term efficacy and effectively reduce the serum oncological index concentration of patients. It can be promoted in clinics. doi: https://doi.org/10.12669/pjms.35.5.591 How to cite this:Zhang S, Zhao S, Fu X. Intensity modulated radiotherapy in combination with endocrinotherapy in the treatment of middle and advanced Prostatic Cancer. Pak J Med Sci. 2019;35(5):---------. doi: https://doi.org/10.12669/pjms.35.5.591 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document